aod9604 - 300mcg troche Aod 9604 AOD 9604 Peptide Therapy -

The most common AEs reported during the study were: Headache (6 times) Fatigue (4) Hypoglycemia unspecified (3) Dizziness (3) Nasopharyngitis (2) Cough (2) Lethargy (1) Tonsillitis (1) Abdominal pain unspecified (1) Application site reaction unspecified (1) Injection site bruising (1) Rhinitis seasonal (1) Anorexia (1) Injection site pain (1) None of the AEs were of severe intensity and there was no observable trend between the different treatment groups with respect to the incidence of certain AEs

However, injections have an important edge over oral supplements that you may not be aware of

Less insulin is needed to manage the same glucose load

It enhances overall well-being, energy, and mood